What it is
Vilon is two amino acids: lysine joined to glutamic acid. PubChem's record (CID 7010502) names it (2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]pentanedioic acid — L-lysyl-L-glutamic acid — with the formula C11H21N3O5 and a molecular weight of 275.30. That formula is exactly what a Lys-Glu dipeptide should have (our check against the residue masses).
Its developers, at the St Petersburg Institute of Bioregulation and Gerontology under V. Khavinson, list it among their peptide bioregulators alongside epitalon, thymalin, cartalax, testagen and vesugen, which adds one amino acid to Vilon's two. Papers from that group call Vilon "thymomimetic" — a short synthetic copy of the kind of signal they attribute to thymus extracts.
What the research shows
The indexed record is small and concentrated. A PubMed search on 2026-11-12 returned 62 records with "vilon" in the title or abstract, from 1997 to 2023; one is an unrelated data-network method that happens to be called ViLoN.
| Kind of study | What was reported | Example records |
|---|---|---|
| Mice | Fewer spontaneous tumours and longer life | Khavinson & Anisimov 2000 (PMID 10944717) |
| Mice, chemical carcinogen | Tumours in 14.3% given 10 µg/kg vs 60% of controls | Pliss et al. 2005 (PMID 16308980) |
| Mouse heart | Gene-expression changes on DNA microarrays, beside epitalon | Anisimov et al. 2002 (Bull Exp Biol Med) |
| Human cells in culture | Chromatin "reactivation" in lymphocytes from old people; thymus-cell and stem-cell gene changes | PMIDs 15105581, 23486604, 37782636 |
| Patients | Clotting and immune markers in type 1 diabetes; survival and complications in elderly colorectal cancer | PMIDs 17152731, 18306698, 16075684 |
Three things the table does not show. The patient papers are Russian-language reports in the programme's own gerontology journal, and their abstracts give no patient count, no control group and no randomisation; the 2005 cancer paper describes its own findings as "preliminary results." A 2013 review by the programme's authors (PMID 24003726) summarises their clinical experience with several bioregulators, including Vilon — a review of their own work, not an independent one. And no study of Vilon is registered on ClinicalTrials.gov: its single match for the word is an unrelated breast-cancer pathology study (NCT02580799, read 2026-11-12).
What is not established
- That the mouse results carry over. Fewer tumours and longer life were measured in mice; no study has looked for either outcome in people.
- What the patient reports actually counted. The diabetes and colorectal-cancer abstracts give no head-count, no control arm and no randomisation, so their marker changes cannot be weighed.
- What happens to Lys-Glu in the body. Whether it stays a dipeptide or is split into its two amino acids after dosing is not measured in any indexed abstract on people.
- An outside confirmation. The biological and clinical papers come from the programme and its collaborators, and the main clinical summary is the 2013 review of its own work.
Where it stands
- Regulatory status: Drugs@FDA and openFDA hold nothing for it, and no paper reports a marketing approval anywhere.
- Where readers meet it: immune and anti-ageing bioregulator listings and research-peptide shops. Their products are not reviewed in this library.
- Size of the record (2026-11-12): 62 PubMed hits from 1997 to 2023, mostly mouse and cell work; no registered trial.
Related reading
The other dipeptide in the same family is Thymogen (Glu-Trp), and the longest-studied member is epitalon, whose record has the same single-programme shape. The thymus extract these short peptides are said to imitate is described in the thymalin entry, and the hormones the thymus really makes are set out in the thymosin entry. For how two amino acids join at all, see the peptide bond entry.
